High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Genomic rearrangements in the MYC locus occur in ∼12% of lymphomas with diffuse large B-cell lymphoma (DLBCL) morphology and are associated with inferior outcome. Previous studies exploring MYC rearrangements have primarily used fluorescence in situ hybridization (FISH) assays to characterize break-apart status but have rarely examined breakpoint location, and in some cases have not examined partner identity. We performed targeted sequencing of MYC, BCL2, BCL6, and the immunoglobulin (IG) loci in 112 tumors with DLBCL morphology harboring MYC rearrangement. We characterized the location of the MYC rearrangement at base pair resolution and identified the partner in 88 cases. We observed a cluster of breakpoints upstream of the MYC coding region and in intron 1 (the "genic cluster"). Genic cluster rearrangements were enriched for translocations involving IGH (80%), whereas nongenic rearrangements occurred mostly downstream of the MYC gene with a variety of partners, including IGL and IGK Other recurrent partners included BCL6, ZCCHC7, and RFTN1, which has not previously been described as a MYC partner. We compared 2 commercially available FISH break-apart assays for the MYC locus and observed discordant results in 32% of cases examined, including some with MYC-IGL and MYC-IGK rearrangements. In cases of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangement (HGBL-DH), so-called "double-hit" lymphomas, the majority of MYC rearrangements had non-IG partners (65%), with breakpoints outside the genic cluster (72%). In patients with de novo HGBL-DH of DLBCL morphology, MYC-IG rearrangements showed a trend toward inferior time to progression and overall survival compared with MYC-non-IG rearrangements. Our data reveal clinically relevant architecture of MYC rearrangements in lymphomas with DLBCL morphology.

[1]  A. Lauritzen,et al.  MYC translocation partner gene determines survival of patients with large B‐cell lymphoma with MYC‐ or double‐hit MYC/BCL2 translocations , 2014, European journal of haematology.

[2]  R. Yeh,et al.  Identification of two distinct MYC breakpoint clusters and their association with various IGH breakpoint regions in the t(8;14) translocations in sporadic Burkitt-lymphoma , 2007, Leukemia.

[3]  F. Jardin,et al.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.

[4]  Shawn M. Gillespie,et al.  Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. , 2015, Cancer discovery.

[5]  Thomas Zichner,et al.  DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..

[6]  R. Spang,et al.  Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.

[7]  A. Rosenwald,et al.  High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. , 2018, Blood.

[8]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[9]  M. Dyer,et al.  BCL2 translocations in leukemias of mature B cells. , 1994, Blood.

[10]  R. Aguiar,et al.  A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma. , 2013, Blood.

[11]  E. Obermann,et al.  Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment , 2009, Journal of Clinical Pathology.

[12]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[13]  Ryan D. Morin,et al.  Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas. , 2016, Blood.

[14]  A. Ariza,et al.  MYC status determination in aggressive B‐cell lymphoma: the impact of FISH probe selection , 2013, Histopathology.

[15]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Advani,et al.  The World Health Organization Classification of Lymphoid Neoplasms , 2013 .

[17]  A. Dogan,et al.  Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2 , 2006, Leukemia.

[18]  Steven J. M. Jones,et al.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.

[19]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[20]  Ken H. Young,et al.  Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma , 2015, Oncotarget.

[21]  D. Arber,et al.  ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. , 2007, The Journal of molecular diagnostics : JMD.

[22]  E. Thiel,et al.  Molecular analysis of the t(2;8)/MYC–IGK translocation in high‐grade lymphoma/leukemia by long‐distance inverse PCR , 2012, Genes, chromosomes & cancer.

[23]  Andreas Trumpp,et al.  A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies , 2018, Nature.

[24]  M. Neat,et al.  Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing. , 2010, Cancer genetics and cytogenetics.

[25]  A. Yoshimura,et al.  The B cell‐specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction , 2003, The EMBO journal.

[26]  A. Rosenwald,et al.  Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. , 2013, Blood.

[27]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[28]  A. Lauritzen,et al.  Double‐hit BCL2/MYC translocations in a consecutive cohort of patients with large B‐cell lymphoma – a single centre's experience , 2012, European journal of haematology.

[29]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Lichter,et al.  Variable breakpoints in Burkitt lymphoma cells with chromosomal t(8;14) translocation separate c-myc and the IgH locus up to several hundred kb. , 1992, Human molecular genetics.

[31]  Philippe Dessen,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology in 2013 , 2012, Nucleic Acids Res..

[32]  G. Klein,et al.  Characteristic chromosomal abnormalities in biopsies and lymphoid‐cell lines from patients with burkitt and non‐burkitt lymphomas , 1976, International journal of cancer.

[33]  C. Copie-Bergman,et al.  MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.

[34]  Olivier Elemento,et al.  Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. , 2016, Immunity.

[35]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[36]  R. Spang,et al.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.

[37]  Kai Fu,et al.  Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. , 2014, Blood.

[38]  G. Morgan,et al.  Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients , 2014, Blood Cancer Journal.

[39]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[40]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[41]  M. Rocchi,et al.  Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma , 2003, Genes, chromosomes & cancer.

[42]  J. Friedberg How I treat double-hit lymphoma. , 2017, Blood.

[43]  Scott E. Smith,et al.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.

[44]  A. Aventín,et al.  A variant translocation t(2;18) in follicular lymphoma involves the 5' end of bcl-2 and Ig kappa light chain gene. , 1991, Oncogene.

[45]  E. Haralambieva,et al.  BCL6 alternative translocation breakpoint cluster region associated with follicular lymphoma grade 3B , 2005, Genes, chromosomes & cancer.

[46]  Patrice Duroux,et al.  IMGT®, the international ImMunoGeneTics information system® 25 years on , 2014, Nucleic Acids Res..

[47]  M. Lieber Mechanisms of human lymphoid chromosomal translocations , 2016, Nature Reviews Cancer.

[48]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[49]  Ioannis Panagopoulos,et al.  Atlas of Genetics and Cytogenetics in Oncology and Haematology , 2005 .

[50]  P. Leder,et al.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.